GTHX Forex-Nachrichten
G1 Therapeutics To Discontinue Phase 3 PRESERVE 1 Trial
Oncology company G1 Therapeutics, Inc. (GTHX) announced Monday topline results from its pivotal Phase 3 PRESERVE 1 trial showing that the trial achieved its co-primary endpoints related to severe neutropenia with statistical significance.
RTTNews
|
vor 731 Tagen
